20845-34-5|1-Methyl-2-piperidinemethanol| Ambeed

Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

{[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

Quality Control of [ 20845-34-5 ] Purity: 98% SDS Specification

COA

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

NMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

CNMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

HPLC

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

LC-MS

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

1-2 Day Shipping
High Quality
Technical Support

Product Details of [ 20845-34-5 ]

CAS No. :	20845-34-5
Formula :	C₇H₁₅NO
M.W :	129.20
SMILES Code :	C(C1N(CCCC1)C)O
MDL No. :	MFCD00006494
InChI Key :	HXXJMMLIEYAFOZ-UHFFFAOYSA-N
Pubchem ID :	89394

Safety of [ 20845-34-5 ]

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H227-H315-H319-H335
Precautionary Statements:	P305+P351+P338

Computational Chemistry of [ 20845-34-5 ] Show Less

Physicochemical Properties

Num. heavy atoms	9
Num. arom. heavy atoms	0
Fraction Csp3	1.0
Num. rotatable bonds	1
Num. H-bond acceptors	2.0
Num. H-bond donors	1.0
Molar Refractivity	41.62
TPSA ? Topological Polar Surface Area: Calculated from Ertl P. et al. 2000 J. Med. Chem.	23.47 Å²

Lipophilicity

Log P_o/w (iLOGP)? iLOGP: in-house physics-based method implemented from Daina A et al. 2014 J. Chem. Inf. Model.	1.72
Log P_o/w (XLOGP3)? XLOGP3: Atomistic and knowledge-based method calculated by XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry	0.49
Log P_o/w (WLOGP)? WLOGP: Atomistic method implemented from Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.	0.08
Log P_o/w (MLOGP)? MLOGP: Topological method implemented from Moriguchi I. et al. 1992 Chem. Pharm. Bull. Moriguchi I. et al. 1994 Chem. Pharm. Bull. Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.	0.57
Log P_o/w (SILICOS-IT)? SILICOS-IT: Hybrid fragmental/topological method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	0.78
Consensus Log P_o/w? Consensus Log P_o/w: Average of all five predictions	0.73

Water Solubility

Log S (ESOL):? ESOL: Topological method implemented from Delaney JS. 2004 J. Chem. Inf. Model.	-0.88
Solubility	16.9 mg/ml ; 0.131 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Very soluble
Log S (Ali)? Ali: Topological method implemented from Ali J. et al. 2012 J. Chem. Inf. Model.	-0.55
Solubility	36.2 mg/ml ; 0.28 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Very soluble
Log S (SILICOS-IT)? SILICOS-IT: Fragmental method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	-0.55
Solubility	36.2 mg/ml ; 0.28 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble

Pharmacokinetics

GI absorption? Gatrointestinal absorption: according to the white of the BOILED-Egg	High
BBB permeant? BBB permeation: according to the yolk of the BOILED-Egg	No
P-gp substrate? P-glycoprotein substrate: SVM model built on 1033 molecules (training set) and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94	No
CYP1A2 inhibitor? Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91	No
CYP2C19 inhibitor? Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86 External: ACC=0.80 / AUC=0.87	No
CYP2C9 inhibitor? Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set) and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85 External: ACC=0.71 / AUC=0.81	No
CYP2D6 inhibitor? Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set) and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87	No
CYP3A4 inhibitor? Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set) and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86	No
Log Kp (skin permeation)? Skin permeation: QSPR model implemented from Potts RO and Guy RH. 1992 Pharm. Res.	-6.74 cm/s

Druglikeness

Lipinski? Lipinski (Pfizer) filter: implemented from Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500 MLOGP ≤ 4.15 N or O ≤ 10 NH or OH ≤ 5	0.0
Ghose? Ghose filter: implemented from Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480 -0.4 ≤ WLOGP ≤ 5.6 40 ≤ MR ≤ 130 20 ≤ atoms ≤ 70	None
Veber? Veber (GSK) filter: implemented from Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10 TPSA ≤ 140	0.0
Egan? Egan (Pharmacia) filter: implemented from Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88 TPSA ≤ 131.6	0.0
Muegge? Muegge (Bayer) filter: implemented from Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600 -2 ≤ XLOGP ≤ 5 TPSA ≤ 150 Num. rings ≤ 7 Num. carbon > 4 Num. heteroatoms > 1 Num. rotatable bonds ≤ 15 H-bond acc. ≤ 10 H-bond don. ≤ 5	1.0
Bioavailability Score? Abbott Bioavailability Score: Probability of F > 10% in rat implemented from Martin YC. 2005 J. Med. Chem.	0.55

Medicinal Chemistry

PAINS? Pan Assay Interference Structures: implemented from Baell JB. & Holloway GA. 2010 J. Med. Chem.	0.0 alert
Brenk? Structural Alert: implemented from Brenk R. et al. 2008 ChemMedChem	0.0 alert: heavy_metal
Leadlikeness? Leadlikeness: implemented from Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350 XLOGP ≤ 3.5 Num. rotatable bonds ≤ 7	No; 1 violation:MW<1.0
Synthetic accessibility? Synthetic accessibility score: from 1 (very easy) to 10 (very difficult) based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties, trained on 12'782'590 molecules and tested on 40 external molecules (r² = 0.94)	1.66

Application In Synthesis of [ 20845-34-5 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Downstream synthetic route of [ 20845-34-5 ]

[ 20845-34-5 ] Synthesis Path-Downstream 1~35

1
[ 116570-78-6 ]
[ 20845-34-5 ]

References: [1]Journal of the American Chemical Society,1958,vol. 80,p. 2743.

2
[ 34285-36-4 ]
[ 20845-34-5 ]

References: [1]Collection of Czechoslovak Chemical Communications,1959,vol. 24,p. 3326,3332.

3
[ 20845-34-5 ]
[ 30293-86-8 ]
[ 147146-14-3 ]

References: [1]Journal of Medicinal Chemistry,1993,vol. 36,p. 320 - 330.

4
[ 20845-34-5 ]
[ 124-63-0 ]
[ 907160-87-6 ]

Yield	Reaction Conditions	Operation in experiment
	With triethylamine; In tetrahydrofuran; at 0 - 23℃; for 1.67h;	To a solution of 1 -methyl-2-piperidine-methanol (Aldrich, 0.27 mL, 2.1 mmol) in 10 mL tetrahydrofuran (THF) at 0 0C was added triethylamine (0.87 mL, 6.22 mmol) followed EPO <DP n="34"/>by methanesulfonyl chloride (0.24 mL, 3.1 mmol). The mixture was stirred at 0 0C for 10 min then the ice-bath was removed and the reaction mixture was stirred at 23 0C for an additional 1.5 h. The reaction mixture was filtered though Celite with THF and concentrated under reduced pressure. This crude material was used directly in the next reaction.

References: [1]Journal of Medicinal Chemistry,1992,vol. 35,p. 4334 - 4343.
[2]Patent: WO2006/69196,2006,A1 .Location in patent: Page/Page column 32-33.
[3]Journal of Medicinal Chemistry,2010,vol. 53,p. 295 - 315.

5
[ 20845-34-5 ]
[ 77042-85-4 ]
[ 77042-72-9 ]

References: [1]Journal of Medicinal Chemistry,1986,vol. 29,p. 1877 - 1888.

6
[ 20845-34-5 ]
[ 109-92-2 ]
[ 129126-29-0 ]

References: [1]Journal of Organic Chemistry,1990,vol. 55,p. 5757 - 5761.

7
[ 98303-20-9 ]
[ 20845-34-5 ]

Yield	Reaction Conditions	Operation in experiment
	With LiAlH4; In tetrahydrofuran;	EXAMPLE 10 1-Methyl-2-piperidinemethanol The title compound of Example 9 (23.2 g, 101 mmol) in dry THF (100 mL) was added dropwise to a 1.0M solution of LiAlH4 in THF (405 mL, 405 mmol, 4eq) and the reaction mixture was refluxed overnight and the product was isolated as described in Example 6 to give the product (13.1 g, quantative) as a colorless oil. The fumarate salt crystallized from 2-propanol: mp 118°-120° C.; 1 H-NMR (CDCl3) dd;3.85 (dd, J=gem=11 Hz, J=3.9 Hz, 1H), 3,39 (dd, J=gem=11 Hz, J=2.2 Hz, 1H), 2.89 (m, 1H), 2.30 (s, 3H), 2.15 (m, 1H), 1.97 (m, 1H), 1.76 (m, 1H), 1.42-1.68 (complex m, 4H), 1.28 (m, 1H); CIMS (MH+ calcd for C7 H15 NO): 130. Found (MH+): 130; Anal. (C11 H19 NO5): C,H,N.

References: [1]Journal of Medicinal Chemistry,1992,vol. 35,p. 4334 - 4343.
[2]Patent: US5571832,1996,A .

8
[ 20845-34-5 ]
[ 79-44-7 ]
Dimethyl-carbamic acid 1-methyl-piperidin-2-ylmethyl ester [ No CAS ]

References: [1]Archiv der Pharmazie,1996,vol. 329,p. 95 - 104.

9
[ 1690-74-0 ]
[ 20845-34-5 ]

References: [1]Journal of Organic Chemistry,1995,vol. 60,p. 5763 - 5769.

10
[ 7730-87-2 ]
[ 20845-34-5 ]

References: [1]Journal of Organic Chemistry,1995,vol. 60,p. 5763 - 5769.

11
[ 20845-34-5 ]
[ 507-09-5 ]
N-methyl-2-(thioacetyl)methylpiperidine [ No CAS ]

References: [1]Journal of Organic Chemistry,1996,vol. 61,p. 2624 - 2631.

12
[ 20845-34-5 ]
3-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-2-(4-triisopropylsilanyloxy-phenyl)-benzo[b]thiophen-6-ol [ No CAS ]
2-(4-(N-methylpiperidino-2-methyloxy)-phenyl)-3-(4'-(2-piperidinoethyloxy)phenyl)-6-hydroxybenzothiophene [ No CAS ]

References: [1]Tetrahedron,1999,vol. 55,p. 11641 - 11652.

Yield	Reaction Conditions	Operation in experiment
99%	With 5percent silver supported on titanium oxide; at 25℃; for 10h;Inert atmosphere; Sealed tube; UV-irradiation;	General procedure: In a glass reaction vessel,2 mmol of 2- (benzylamino) ethanol, 45 mg of catalyst D,20 mL of dehydrated methanol, and a magnetic stirrer.Then, an argon gas was introduced into the sealed reaction system, and under a condition of 25 ° C.,While stirring the reaction system, ultraviolet rays were irradiated for 10 hours.When the reaction solution was subjected to GC-MS analysis,Only 2- (N-methylbenzylamino) ethanol was obtained(Yield 87percent, see Table 3).
		Then, a dichloromethane (30 ml) solution of (-)-1-methyl-2-piperidinemethanol (3.04 g, 23.8 mmol) produced in Reference Example 7 was dropwise added, and the mixture was stirred at -78° C. for 30 min. Triethylamine (22 ml, 150 mmol) was slowly dropped, and the mixture was stirred for 15 min. Temperature of the resulting mixture was raised to approximately 10° C. followed by addition of water (65 ml). The organic layer was separated, and the aqueous layer was extracted with chloroform (2100 ml). The combined organic layers were washed with saturated aqueous sodium chloride and dried over anhydrous magnesium sulfate. The solvent was removed under reduced pressure to give a crude product as a brown oil (3.00 g). The crude aldehyde thus obtained was used immediately in the next step without any further purification. To a solution of the crude aldehyde (3.00 g, 33.8 mmol) in ether (100 ml) was dropwise added under ice-cooling a 1.0M ether solution of methylmagnesium iodide (25 ml, 25 mmol). Subsequently, the mixture was stirred at room temperature for 2 hours followed by addition of a saturated aqueous ammonium chloride (50 ml). The mixture was extracted with chloroform (2100 ml), and the organic layers were washed with saturated aqueous sodium chloride and dried over anhydrous magnesium sulfate.
	With lithium aluminium tetrahydride; In tetrahydrofuran; at 0 - 20℃; for 3.16667h;Inert atmosphere;	General procedure: A solution of tert-butyl (3R)-3-(hydroxymethyl)piperidine-1-carboxylate (1.07 g,4.98 mmol) in dry THF (10 mL) was stirred under N2 and cooled in an ice-water bath. A 2M solution of LiA1H4 in THF (3.0 mL, 5.97 mmol) was added dropwise over a period of10 minutes. The mixture was stirred at 0 °C and gradually allowed to warm to roomtemperature over 3 hours. After stirring at room temperature overnight the mixture wascooled in an ice-bath and a 1 N solution of NaOH (1 mL) was added dropwise over a periodof 10 minutes followed by water (0.5 mL). The mixture was stirred at room temperature for 3 hours, filtered through a Celite® cartridge which was then washed through with THF and the combined filtrates were concentrated in vacuo to give the title product as a yellow oil(0.61 g, 95percent).

15
(+-)-1-methyl-piperidine-2-carboxylic acid ethyl ester [ No CAS ]
[ 20845-34-5 ]

References: [1]Journal of the American Chemical Society,1952,vol. 74,p. 3831.

16
(+-)-<1-formyl-<2>piperidyl>-methanol [ No CAS ]
[ 20845-34-5 ]

References: [1]Journal of the American Chemical Society,1955,vol. 77,p. 29.

17
[ 20845-34-5 ]
2.) 1,3-dimethyl-2-fluorobenzenetricarbonylchromium [ No CAS ]
(+/-)-2-(2,6-dimethylphenoxymethyl)-1-methylpiperidine hydrochloride [ No CAS ]

References: [1]Journal of Organic Chemistry,1999,vol. 64,p. 3373 - 3375.

18
[ 20845-34-5 ]
p-methoxybenzyl 7β-[2(Z)-(2-tritylaminothiazol-4-yl)-2-methoxyiminoacetamido]-3-[(Z)-3-chloro-1-propen-1-yl]-3-cephem-4-carboxylate [ No CAS ]
C₂₃H₃₀N₆O₆S₂ [ No CAS ]

References: [1]Journal of Antibiotics,1996,vol. 49,p. 1286 - 1289.

19
[ 20845-34-5 ]
[ 931-20-4 ]

References: [1]Synlett,2002,p. 2092 - 2094.

20
[ 20845-34-5 ]
[ 41467-01-0 ]

Yield	Reaction Conditions	Operation in experiment
31%		Step 11-Methylpiperidine-2-carbaldehydeDimethyl sulfoxide (3.3 mL, 46 mmol) was dissolved in 15 mL of dichloromethane in a dry ice bath, followed by dropwise slowly addition of oxalyl chloride (2.6 mL, 31 mmol).After stirring for 45 minutes, a solution of (1-methyl-2-piperidyl)methanol 6a (1 g, 7.74 mmol) in 5 mL of dichloromethane was added dropwise to the solution.The reaction mixture was stirred for 45 minutes, then added with triethylamine (7.2 mL, 52 mmol), and stirred for 10 minutes, then warmed up to room temperature and stirred for 1 hour.The reaction mixture was washed with water (20 mL) and saturated brine (20 mL) successively.The combined organic extracts were dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure then the resulting residue was purified by alkaline alumina column chromatography with elution system A to obtain the title compound 1-methylpiperidine-2-carbaldehyde 6b (300 mg, yield 31.0percent) as a brown oil, which was directly used in the next step without purification.
		DMSO (122 mg, 1.56 mmol) in DCM (0.5 mL) was cooled to -78°C, and trifluoroacetic acid anhydride (246 mg, 1.17 mmol) in DCM (0.5 mL) was added slowly. The mixture was stirred at -78°C for 45 min. Subsequently, a solution of (l-methylpiperidin-2-yl)methanol (101 mg, 0.78 mmol) in DCM (1.0 mL) was added dropwise, and the mixture was kept at -78°C for 1 h. Triethyl- amine (99 mg, 0.98 mmol) was added, and the mixture was slowly warmed to rt. The mixture was then diluted with tert-butyl methyl ether/DCM (1 :1) and extracted with 1 N hydrochloric acid. The aqueous phase was washed twice with tert-butyl methyl ether, then basifed with sodium carbonate <n="153"/>solution and extracted with tert-butyl methyl ether. The organic phase was dried over sodium sulfate, and the solvent was carefully removed in vacuo. The residue was dissolved in THF (1.0 mL) to give solution A.
		Under dry ice bath, dimethylsulfoxide (3.3 mL, 46 mmol) was dissolved in 15 mL of methylene chloride. It was slowly added dropwise oxalyl chloride (2.6 mL, 31 mmol). The reaction was stirred for 45 minutes. Add dropwise 5 mL (1-methyl-2-piperidine)methanol 6a (1 g, 7.74 mmol) in methylene chloride. The reaction was continued for 45 minutes. Add triethylamine (7.2 mL, 52 mmol). The reaction was stirred for 10 minutes. At room temperature react for one hour. The reaction mixture was washed successively with water (20 mL) and washed with saturated sodium chloride solution (20 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure, column chromatography using basic alumina A to the resulting residue was purified eluent system to give the title product, 1-methyl - piperidin-2-carbaldehyde 6b (300 mg, brown liquid), yield: 31.0percent, crude without purification directly to the next reaction.

References: [1]Patent: US2012/165352,2012,A1 .Location in patent: Page/Page column 25-26.
[2]Bioorganic and Medicinal Chemistry Letters,2003,vol. 13,p. 3847 - 3851.
[3]Patent: WO2009/33581,2009,A1 .Location in patent: Page/Page column 151-152.
[4]Patent: TWI524893,2016,B .Location in patent: Page/Page column 47.

21
[ 20845-34-5 ]
[ 49665-74-9 ]

Yield	Reaction Conditions	Operation in experiment
34%	With thionyl chloride; In chloroform;	EXAMPLE 4 1-Methyl-2-[(N-phenyl-N-2-indanyl)aminomethyl]piperidine HCI (TAC 29) Treatment of 1-methyl-2-piperidinemethanol (12.9 g, 0.1 mol) with thionyl chloride (7.6 ml) in chloroform (40 ml), as described in example 3, gave 1-methyl-2-(chloromethyl) piperidine (5.0 g, 34percent).
		14.1. 4-[(1-Methylazepan-3-yl)oxy]benzaldehyde and4-[(1-methylpiperidin-2-yl)methoxy]benzaldehyde To a solution of 2.59 g (21.2 mmol) 2-chloromethyl-1N-methylpiperidine (obtained by reacting 1N-methylpiperidine-2-ylmethanol with SOCl2, hydrolysis with N NaOH and then extraction with dichloromethane) and 3.13 g (21.2 mmol) of 4-hydroxybenzaldehyde in 42 mL of DMF are added 2.93 g (21.2 mmol) of potassium carbonate. The mixture is stirred at 80° C. for 4 hours and, after cooling, is then poured into water and extracted with ethyl acetate. The organic extract is washed with water and then with saturated aqueous sodium chloride, dried over anhydrous sodium sulfate and then evaporated under reduced pressure. 900 mg of the residue obtained are purified on a column of silica gel (solvent: dichloromethane/methanol from 100/0 to 95/5 (v/v)). 360 mg of 4-[(1-methylazepan-3-yl)oxy]benzaldehyde and 192 mg of 4-[(1-methylpiperidin-2-yl)methoxy]benzaldehyde are obtained. These products are oily.4-[(1-Methylazepan-3-yl)oxy]benzaldehyde:1H NMR (DMSO-d6, 400 MHz) delta ppm: 1.48-1.80 (m, 5H); 2.0-2.10 (m, 1H); 2.31 (s, 3H); 2.45-2.55 (m, 1H); 2.55-2.70 (m, 2H); 2.82-2.90 (m, 1H); 4.18-4.23 (m, 1H); 7.14 (d, J=9 Hz, 2H), 7.84 (d, J=9 Hz, 2H), 9.86 (s, 1H, CHO).4-[(1-Methylpiperidin-2-yl)methoxy]benzaldehyde:1H NMR (DMSO-d6, 400 MHz) delta ppm: 1.20-1.60 (m, 4H); 1.68-1.80 (m, 2H); 2.02-2.10 (m, 1H); 2.20-2.27 (m, 1H); 2.24 (s, 3H); 2.74-2.80 (m, 1H); 4.0-4.05 (m, 1H); 4.18-4.22 (m, 1H); 7.13 (d, J=9 Hz, 2H), 7.85 (d, J=9 Hz, 2H), 9.88 (s, 1H, CHO).

References: [1]Patent: US6413987,2002,B1 .
[2]Bioorganic and Medicinal Chemistry Letters,2003,vol. 13,p. 3847 - 3851.
[3]Patent: US2009/124624,2009,A1 .Location in patent: Page/Page column 30.

22
[ 20845-34-5 ]
[ 622369-46-4 ]
4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[(1-methylpiperidine-2-yl)methoxy]quinoline-3-carbonitrile [ No CAS ]

References: [1]Journal of Medicinal Chemistry,2004,vol. 47,p. 1599 - 1601.

23
[ 67-56-1 ]
[ 3433-37-2 ]
[ 20845-34-5 ]

References: [1]European Journal of Inorganic Chemistry,2004,p. 524 - 529.
[2]Organic Letters,2018,vol. 20,p. 5985 - 5990.

24
[ 20845-34-5 ]
[ 530-62-1 ]
2-imidazol-1-ylmethyl-1-methyl-piperidine [ No CAS ]
imidazole-1-carboxylic acid 1-methyl-piperidin-2-ylmethyl ester [ No CAS ]
carbonic acid bis-(1-methyl-piperidin-2-ylmethyl) ester [ No CAS ]

References: [1]Synthesis,2004,p. 2540 - 2544.

25
[ 20845-34-5 ]
[ 202931-56-4 ]
C₂₄H₂₉N₅O [ No CAS ]

References: [1]Journal of Medicinal Chemistry,2005,vol. 48,p. 1367 - 1383.

26
[ 658085-52-0 ]
[ 20845-34-5 ]
[4-(2,4-difluoro-5-methoxycarbamoyl-phenylamino)-5-isopropyl-pyrrolo[2,1-f][1,2,4]triazin-6-yl]-carbamic acid 1-methyl-piperidin-2-ylmethyl ester [ No CAS ]

References: [1]Journal of Medicinal Chemistry,2005,vol. 48,p. 3991 - 4008.

27
[ 20845-34-5 ]
[ 27483-92-7 ]

Yield	Reaction Conditions	Operation in experiment
	With thionyl chloride; In ethanol; chloroform;	The 1-methylpiperidin-2-ylmethyl chloride hydrochloride used as a starting material was prepared as follows: Hydrogen chloride gas was bubbled into a solution of 1-methyl-2-piperidinemethanol (12.9 g) in chloroform (80 ml) until two layers developed. The resultant mixture was heated to reflux and thionyl chloride (29 ml) was added slowly. The mixture was stirred and heated to reflux for a further hour. The mixture was evaporated, ethanol was added and the mixture was re-evaporated. The residue was dissolved in ethanol and the solution was decolourised with charcoal. The clear filtrate was diluted with diethyl ether until turbidity occurred. The required compound (12 g) crystallized from the solution; m.p. 159-162° C.; Mass: M+H+147.

References: [1]Journal of Medicinal Chemistry,2005,vol. 48,p. 6386 - 6392.
[2]Patent: US6593333,2003,B1 .

28
[ 20845-34-5 ]
[ 23138-55-8 ]
(3-bromo-phenyl)-carbamic 1-methyl-piperidin-2-yl-methyl ester [ No CAS ]